RAPP in den Nachrichten
Präzision, Empathie, Wachstumsaktivierung
Tamtam hat 20 aktuelle Artikel über RAPP gefunden.
- Analysts Conflicted on These NA Names: General Dynamics (GD), Rapport Therapeutics, Inc. (RAPP) and First Solar (FSLR)
- Market Movers | Winners: QNC, EGHT, FSLY | Losers: CGEM, ALKT, RAPP
- Rapport Therapeutics (RAPP) officer flags $553K stock sale plan
- Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month High - Should You Buy?
- Rapport Therapeutics (RAPP) CEO Abraham Ceesay sells 51,499 shares via 10b5-1 plan
- Omnicom moves Rapp into Critical Mass and global CEO exits in restructure
- RAPP: RAP-219 shows strong efficacy in epilepsy, with phase III and LAI programs advancing
- Third Rock sells shares of RAPP (NASDAQ: RAPP) under Form 144
- (RAPP) Volatility Zones as Tactical Triggers
- Form 144 shows proposed 500-share sale; insider 10b5-1 trades (RAPP)
- Form 144: Morgan Stanley Smith Barney (NASDAQ: RAPP) lists 360-share sale
- Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Moderate Buy" by Analysts
- Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform?
- (RAPP) Risk Channels and Responsive Allocation
- How Rapport’s Greater China RAP-219 Licensing Deal At Rapport Therapeutics (RAPP) Has Changed Its Investment Story
- Rapp at Home receives grant to reduce risk of social isolation
- Marketing Skills Trust, Ogilvy and Rapp to run mentorships in memory of ex-Ogilvy chief
- New Analyst Forecast: $RAPP Given $47 Price Target
- Could RAP-219’s Upcoming Data Reveal a Turning Point for Rapport Therapeutics’ Pipeline Strategy (RAPP)?
- New Analyst Forecast: $RAPP Given $47.0 Price Target
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie RAPP?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden